Hancock Jaffe Laboratories Inc (NASDAQ:HJLI) saw a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 20,800 shares, a decrease of 11.9% from the July 31st total of 23,600 shares. Based on an average daily trading volume, of 244,900 shares, the short-interest ratio is presently 0.1 days. Approximately 0.2% of the company’s stock are short sold.
An institutional investor recently bought a new position in Hancock Jaffe Laboratories stock. Jane Street Group LLC purchased a new stake in Hancock Jaffe Laboratories Inc (NASDAQ:HJLI) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 77,915 shares of the company’s stock, valued at approximately $81,000. Jane Street Group LLC owned about 0.43% of Hancock Jaffe Laboratories as of its most recent filing with the Securities and Exchange Commission (SEC). 1.29% of the stock is currently owned by hedge funds and other institutional investors.
Several equities research analysts have recently weighed in on the company. Maxim Group reaffirmed a “buy” rating and issued a $3.00 target price on shares of Hancock Jaffe Laboratories in a research report on Thursday, August 15th. ValuEngine downgraded Hancock Jaffe Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, September 4th. Finally, Zacks Investment Research downgraded Hancock Jaffe Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, June 26th.
HJLI traded down $0.01 on Friday, reaching $0.96. The company’s stock had a trading volume of 84,373 shares, compared to its average volume of 47,197. Hancock Jaffe Laboratories has a 1 year low of $0.87 and a 1 year high of $3.45. The company has a current ratio of 2.46, a quick ratio of 2.46 and a debt-to-equity ratio of 0.15. The business’s 50 day moving average is $1.03 and its 200 day moving average is $1.51.
Hancock Jaffe Laboratories (NASDAQ:HJLI) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.13) EPS for the quarter. Hancock Jaffe Laboratories had a negative net margin of 5,250.79% and a negative return on equity of 207.10%.
Hancock Jaffe Laboratories Company Profile
Hancock Jaffe Laboratories, Inc, a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease.
Receive News & Ratings for Hancock Jaffe Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hancock Jaffe Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.